IP Library › Granted Patent US 12,188,023
Granted Patent B2
US 12,188,023 · App. 17/935,139 · Granted Jan 7, 2025

Display systems for proteins of interest

Inventor: Francisco Ylera (Munich, DE)
Assignee: BIO-RAD ABD SEROTEC GMBH
C12N15/70C07K16/241C07K16/32C07K19/00C12N7/00C12N15/1037C12N15/85C07K2317/21C07K2317/24C07K2317/55C12N2795/00051
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,188,023
App. No.
17/935,139
Granted
Jan 7, 2025
Kind
B2
Abstract

Described herein is a protein display selection method which uncouples a protein of interest (POI) library from the display selection system. Display of the POI can be achieved by forming a covalent bond between the POI and the anchor protein post expression either by enzymatic protein ligation (e.g. SpyLigase, SnoopLigase, sortase, butelase, peptiligase etc.) or by spontaneous covalent bond formation (e.g. SpyTag/SpyCatcher, SnoopTag/SnoopCatcher, etc.). The POI library is fused to a tethering sequence, for example SpyTag, at the C-terminus of the POI which then forms a covalent bond to a capture sequence found on an anchor protein, for example, the SpyCatcher-fused anchor protein, e.g., a SpyCatcher-geneIII protein (SpyCatcher-pIII) fusion, for the most common form of phage display. Nucleic acid constructs, host cell systems and methods of producing the protein display systems are also provided.

Claims (60)

1. A combination of vectors comprising:

a) a first vector comprising a genetic construct (GC1) comprising polynucleotide encoding a protein of interest (POI) fused, in frame, to a tether sequence; and

b) a second vector comprising a genetic construct (GC2) comprising polynucleotide encoding an anchor protein fused, in frame, to a capture sequence, the tether sequence and capture sequence forming a covalent bond when brought into contact with one another either spontaneously or with the help of an enzyme; or a combination of vectors comprising:

a) a first vector comprising a genetic construct (GC1) comprising polynucleotide encoding a protein of interest (POI) fused, in frame, to a capture sequence; and

b) a second vector comprising a genetic construct (GC2) comprising polynucleotide encoding an anchor protein fused, in frame, to a tether sequence, the tether sequence and capture sequence forming a covalent bond when brought into contact with one another either spontaneously or with the help of an enzyme, wherein:

said anchor protein is selected from alpha-agglutinin 1, alpha-agglutinin 2, Cwp1, Cwp2, Gas1p, Yap3p, Flo1p, Crh2p, Pir1, Pir2, Pir4, Icwp, HpSEDI, HpGASI, HpTIPI, HPWPI, HwpIp, Als3p, or Rbt5;

said tether sequence comprises SEQ ID NO: 27, a sequence having at least 70% sequence identity to SEQ ID NO: 27, SEQ ID NO: 34, or SEQ ID NO: 48;

said capture sequence comprises SEQ ID NO: 28, a sequence having at least 90% sequence identity to SEQ ID NO: 28, or amino acids 22-137 of SEQ ID NO: 30; and

said POI is selected from antibodies, antibody fragments, single chain antibodies, scFv, scFab, or single domain antibodies.

2. The combination of vectors according to claim 1 , wherein each vector comprises transcriptional or translational control sequences for expressing the POI and anchor protein.

3. The combination of vectors according to claim 2 , wherein said transcription or translational control sequences are selected from replication origins, promoters, enhancers, repressor binding regions, transcription initiation sites, ribosome binding sites, translation initiation sites, and termination sites for transcription and translation.

4. A yeast host cell comprising a combination of vectors according to claim 1 .

5. The combination of vectors according to claim 1 , wherein:

said anchor protein is alpha-agglutinin 1;

said tether sequence comprises SEQ ID NO: 27; and

said capture sequence comprises SEQ ID NO: 28.

6. The combination of vectors according to claim 1 , wherein:

said anchor protein is alpha-agglutinin 1;

said tether sequence comprises a sequence having at least 70% sequence identity to SEQ ID NO: 27; and

said capture sequence comprises SEQ ID NO: 28.

7. The combination of vectors according to claim 1 , wherein:

said anchor protein is alpha-agglutinin 1;

said tether sequence comprises SEQ ID NO: 48; and

said capture sequence comprises SEQ ID NO: 28.

8. The combination of vectors according to claim 1 , wherein:

said anchor protein is alpha-agglutinin 1;

said tether sequence comprises SEQ ID NO: 34; and

said capture sequence comprises SEQ ID NO: 28.

9. The combination of vectors according to claim 1 , wherein:

said anchor protein is alpha-agglutinin 1;

said tether sequence comprises SEQ ID NO: 27; and

said capture sequence comprises a sequence having at least 90% sequence identity to SEQ ID NO: 28.

10. The combination of vectors according to claim 1 , wherein:

said anchor protein is alpha-agglutinin 1;

said tether sequence comprises a sequence having at least 70% sequence identity to SEQ ID NO: 27; and

said capture sequence comprises a sequence having at least 90% sequence identity to SEQ ID NO: 28.

11. The combination of vectors according to claim 1 , wherein:

said anchor protein is alpha-agglutinin 1;

said tether sequence comprises SEQ ID NO: 48; and

said capture sequence comprises a sequence having at least 90% sequence identity to SEQ ID NO: 28.

12. The combination of vectors according to claim 1 , wherein:

said anchor protein is alpha-agglutinin 1;

said tether sequence comprises SEQ ID NO: 34; and

said capture sequence comprises a sequence having at least 90% sequence identity to SEQ ID NO: 28.

13. The combination of vectors according to claim 1 , wherein:

said anchor protein is alpha-agglutinin 1;

said tether sequence comprises SEQ ID NO: 27; and

said capture sequence comprises amino acids 22-137 of SEQ ID NO: 30.

14. The combination of vectors according to claim 1 , wherein:

said anchor protein is alpha-agglutinin 1;

said tether sequence comprises a sequence having at least 70% sequence identity to SEQ ID NO: 27; and

said capture sequence comprises amino acids 22-137 of SEQ ID NO: 30.

15. The combination of vectors according to claim 1 , wherein:

said anchor protein is alpha-agglutinin 1;

said tether sequence comprises SEQ ID NO: 34; and

said capture sequence comprises amino acids 22-137 of SEQ ID NO: 30.

16. The combination of vectors according to claim 1 , wherein:

said anchor protein is alpha-agglutinin 1;

said tether sequence comprises SEQ ID NO: 48; and

said capture sequence comprises amino acids 22-137 of SEQ ID NO: 30.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2022
From: YLERA, FRANCISCO
To: BIO-RAD ABD SEROTEC GMBH
Reel/Frame 061210/0956 →
Continuity (3)
Division 16375894 · Apr 5, 2019
Provisional Application 62652938 · Apr 5, 2018
Related Publication 20230193297A1 · Jun 22, 2023
References Cited (165)
US 5264365A · Georgiou et al. · 1993 [cited by applicant]
US 5616686A · Fischetti et al. · 1997 [cited by applicant]
US 6753136B2 · Lohning · 2004 [cited by applicant]
US 6828121B2 · Chen · 2004 [cited by applicant]
US 7785859B2 · Lohning · 2010 [cited by applicant]
US 7811973B2 · Burioni et al. · 2010 [cited by applicant]
US 8216822B2 · Mehta et al. · 2012 [cited by applicant]
US 8735330B2 · Løset · 2014 [cited by applicant]
US 8969038B2 · Ellis et al. · 2015 [cited by applicant]
US 8969039B2 · Ellis et al. · 2015 [cited by applicant]
US 9062097B2 · Prassler et al. · 2015 [cited by applicant]
US 9109216B2 · Ellis et al. · 2015 [cited by applicant]
US 9133500B2 · Frisch et al. · 2015 [cited by applicant]
US 9481715B2 · Vernet et al. · 2016 [cited by applicant]
US 9547003B2 · Howarth · 2017 [cited by applicant]
US 9688775B2 · Simmons et al. · 2017 [cited by applicant]
US 9725516B2 · Walper et al. · 2017 [cited by applicant]
US 9951365B2 · Bassett et al. · 2018 [cited by applicant]
US 9994622B2 · Blais et al. · 2018 [cited by applicant]
US 10526379B2 · Howarth · 2020 [cited by applicant]
US 10745730B2 · Gottesman · 2020 [cited by applicant]
US 11059867B2 · Howarth · 2021 [cited by examiner]
US 11453883B2 · Ylera · 2022 [cited by applicant]
US 11674164B2 · Hentrich et al. · 2023 [cited by applicant]
US 20030198956A1 · Makowski et al. · 2003 [cited by applicant]
US 20120259101A1 · Tan et al. · 2012 [cited by applicant]
US 20130029377A1 · Caparon et al. · 2013 [cited by applicant]
US 20140323691A1 · Tan et al. · 2014 [cited by applicant]
US 20160222372A1 · Walper · 2016 [cited by examiner]
US 20160305947A1 · Pierce et al. · 2016 [cited by applicant]
US 20170146522A1 · Howarth · 2017 [cited by applicant]
US 20180052081A1 · Kohman · 2018 [cited by applicant]
US 20180327446A1 · Fong et al. · 2018 [cited by applicant]
US 20180344871A1 · Tsourkas et al. · 2018 [cited by applicant]
US 20190178878A1 · Howarth · 2019 [cited by applicant]
US 20200299358A1 · Knappik et al. · 2020 [cited by applicant]
US 20200299369A1 · Knappik · 2020 [cited by applicant]
US 20200299746A1 · Hentrich et al. · 2020 [cited by applicant]
US 20220135628A1 · Howarth et al. · 2022 [cited by applicant]
CN 101258243 · 2008 [cited by applicant]
CN 101802195 · 2010 [cited by applicant]
CN 103074359 · 2013 [cited by applicant]
CN 108697733 · 2017 [cited by applicant]
CN 106967658 · 2020 [cited by applicant]
EP 0393045 · 1990 [cited by applicant]
EP 1341899 · 2003 [cited by applicant]
EP 1144607 · 2008 [cited by applicant]
EP 2190987 · 2012 [cited by applicant]
EP 2534484 · 2014 [cited by applicant]
EP 2993231 · 2016 [cited by applicant]
KR 102235549 · 2021 [cited by applicant]
WO WO2011098772 · 2011 [cited by applicant]
WO WO2013045632 · 2013 [cited by applicant]
WO WO2013171156 · 2013 [cited by applicant]
WO WO2016154621 · 2016 [cited by applicant]
WO WO2016183387 · 2016 [cited by applicant]
WO WO2016193746 · 2016 [cited by applicant]
WO WO2017058114 · 2017 [cited by applicant]
WO WO2017070742 · 2017 [cited by applicant]
WO WO2017112784 · 2017 [cited by applicant]
WO WO2018053180 · 2018 [cited by applicant]
WO WO2018189517 · 2018 [cited by applicant]
WO WO2018197854 · 2018 [cited by applicant]
WO WO2018220386 · 2018 [cited by applicant]
WO WO2019006046 · 2019 [cited by applicant]
Albrecht, Hugette et al. “Production of Soluble ScFvs with C-Terminal-Free Thiol for Site-Specific Conjugation or Stable Dimeric ScFvs on Demand,” Bioconjugate Chem. Dec. 31, 2003, vol. 15, No. 1, pp. 16-26. [cited by applicant]
Fierer, Jacob O. et al. “SpyLigase peptide-peptide ligation polymerizes affibodies to enhance magnetic cancer cell capture,” PNAS, 2014, pp. 1-6. [cited by applicant]
Mazor, Yariv et al. “Selection of full-length IgGs by tandem display on filamentous phage particles and [cited by applicant]
Nguyen et al. “Butelase 1 is an Asx-specific ligase enabling peptide macrocyclization and synthesis,” nature chemical biology, vol. 10, Jul. 20, 2014, pp. 732-738. [cited by applicant]
Qi, Huan et al. “Phagemid Vectors for Phage Display: Properties, Characteristics and Construction,” Journal of Molecular Biology, Jan. 30, 2012, vol. 417, pp. 129-143. [cited by applicant]
Reddignton, Samuel et al. Secrets of a covalent interaction for biomaterials and biotechnology: SpyTag and SpyCatcher, Current Opinion in Chemical Biology, Oct. 20, 2015, vol. 29, pp. 94-99. [cited by applicant]
Rondot, Susanne et al. “A helper phage to improve single-chain antibody presentation in phage display,” Nature Biotechnology, Jan. 2001, vol. 19, pp. 75-78. [cited by applicant]
Rothe, Christine et al. “The Human Combinatorial Antibody Library HuCAL Gold Combines Diversification of All Six CDRs According to the Natural Immune System with a Novel Display Method for Efficient Selection of High-Af… [cited by applicant]
Thiel, Ilka V. et al. “An Atypical Naturally Split Intein Engineered for Highly Efficient Protein Labeling,” Angew. Chem. Int. Ed., 2014, vol. 53, 1306-1310. [cited by applicant]
Toplak, Ana et al. “Peptiligase, an Enzyme for Efficient Chemoenzymatic Peptide Synthesis and Cyclization in Water,” Adv. Synth. Catal. May 24, 2016, vol. 358, pp. 2140-2147. [cited by applicant]
Veggiani, Gianluca et al. “Programmable polyproteams built using twin peptide superglues,” PNAS, Feb. 2, 2016, vol. 113, No. 5, pp. 1202-1207. [cited by applicant]
Wang, Kevin Caili et al. “Adapter-Directed Display: A Modular Design for Shutting Display on Phage Surfaces,” J. Mol. Biol. , Dec. 4, 2009, vol. 395, 1088-1101. [cited by applicant]
Ward, R.L. et al. “Retrieval of human antibodies from phage-display libraries using enzymatic cleavage,” Journal of Immunological Methods, 1996, vol. 189, pp. 73-82. [cited by applicant]
Yumura, Kyohei et al. “Use of SpyTag/SpyCatcher to construct bispecific antibodies that target two epitopes of a single antigen,” Oxford University Press on behalf of Japanese Biochemical Society, 2017, pp. 1-27. [cited by applicant]
Zakeri, Bijan et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin, PNAS, vol. 109, No. 12, Mar. 20, 2012, pp. 4347-4348. [cited by applicant]
Schmohl, Lena et al. “Sortase-mediated ligations for the site-specific modification of proteins,” Current Opinion in Chemical Biology, Oct. 6, 2014, vol. 22, pp. 122-128. [cited by applicant]
Siegmund, Vanessa et al. “Spontaneous Isopeptide Bond Formation as a Powerful Tool for Engineering Site-Specific Antibody-Drug Conjugates,” Scientific Reports, Dec. 16, 2016, 6:39291, DOI: 10.103/srep39291, pp. 1-9. [cited by applicant]
Van Den Berg van Saparoea, H. B. et al. “Display of Recombinant Proteins on Bacterial Outer Membrane Vesicles by Using Protein Ligation” [cited by applicant]
Schmohl, L. et al. “Engineering sortase A by screening a second-generation library using phage display” [cited by applicant]
Nguyen, H. D. et al. “Analysis and application of [cited by applicant]
Borodina, I. et al. “Disply of wasp venom allergens on the cell surface of [cited by applicant]
Hatlem, D. et al. “Catching a SPY: Using the SpyCatcher-SpyTag and Related Systems for Labeling and Localizing Bacterial Proteins” [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/IB2019/000339, Sep. 13, 2019, pp. 1-22. [cited by applicant]
Alam, M. K. et al. “Site-Specific Fluorescent Labeling of Antibodies and Diabodies Using SpyTag/SpyCatcher System for In Vivo Optical Imaging” [cited by applicant]
Alam, M. K. et al. “Synthetic Modular Antibody Construction Using the SpyTag/SpyCatcher Protein Ligase System” [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/IB2020/000197, Aug. 28, 2020, pp. 1-18. [cited by applicant]
Keeble, A. H. et al. “Evolving Accelerated Amidation by SpyTag/SpyCatcher to Analyze Membrane Dynamics” [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/IB2020/000134, Aug. 27, 2020, pp. 1-18. [cited by applicant]
Meerman, H. et al. “Construction and Characterization of a Set of [cited by applicant]
Chen, C. et al. “High-Level Accumulation of a Recombinant Antibody Fragment in the Periplasm of [cited by applicant]
Ellis, M. et al. “Development of a High Yielding [cited by applicant]
Alves, N. J. et al. “Bacterial Nanobioreactors-Directing Enzyme Packaging into Bacterial Outer Membrane Vesicles” [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/IB2020/000172, Jul. 27, 2020, pp. 1-18. [cited by applicant]
Zakeri, B. et al. “Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin” [cited by applicant]
Liu, Z. et al. “A novel method for synthetic vaccine construction based on protein assembly” [cited by applicant]
Brune, K. D. et al. “Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization” [cited by applicant]
Abe, H. et al. “Split Spy0128 as a Potent Scaffold for Protein Cross-Linking and Immobilization” Bioconjugate Chem., 2013, vol. 24, No. 2, pp. 242-250. [cited by applicant]
Akiba, H. et al. “Generation of biparatopic antibody through two-step targeting of fragment antibodies on antigen using SpyTag and SpyCatcher” [cited by applicant]
Alam, M. et al. “A novel synthetic trivalent single chain variable fragment (tri-scFv) construction platform based on the SpyTag/SpyCatcher protein ligase system.” BMC Biotechnology, 2018, vol. 18, No. 55, pp. 1-8. [cited by applicant]
Albrecht, H. et al. “Monospecific bivalent scFv-SH: Effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility” [cited by applicant]
Batonick, M. et al. “pMINERVA: A donor-Acceptor System for the in vivo Recombineering of scFv into IgG molecules.” J Immunol Methods, 2016 vol. 431, pp. 22-30. [cited by applicant]
Berman, H.M. et al. “The Protein Data Bank.” Nucleic Acids Res. 2000, vol. 28, No. 1, pp. 235-242. [cited by applicant]
Brannon, J.R. “Inhibition of Outer Membrane Proteases of the Omptin Family by Aprotinin,” Infect Immun., 2015, vol. 83, pp. 2300-2311. [cited by applicant]
Caspi, J. et al. “Distribution of split DnaE inteins in cyanobacteria,” Mol Microbiol, 2003, vol. 50, No. 5, pp. 1569-1577. [cited by applicant]
Chen, W. and Georgiou, G., 2002, “Cell-surface display of heterologous proteins: From high-throughput screening to environmental applications,” Biotechnol Bioeng. 79:496-503. [cited by applicant]
Chen, X. et al. “Fusion protein linkers: Property, design and functionality” [cited by applicant]
Chichili et al. “Linkers in the structural biology of protein-protein interactions,” Protein Sci., Sep. 7, 2012, vol. 22:153-167. [cited by applicant]
Cho, M.S. Establishment of a Human Somatic Hybrid Cell Line for Recombinant Protein Production. J Biomed Sci., 2002, vol. 9, pp. 631-638. [cited by applicant]
Choi, J. et al. “Protein Trans-splicing and Characterization of a Split Family B-type DNA Polymerase from the Hyperthermophilic Archaeal Parasite Nanoarchaeum equitans,” J Mol. Biol., 2006, vol. 356, pp. 1093-1106. [cited by applicant]
Cloutier, S. et al. “Streptabody, a high avidity molecule made by tetramerization of in vivo biotinylated, phage display-selected scFv fragments on streptavidin,” Molecular Immunology, 2000, vol. 37, pp. 1067-1077. [cited by applicant]
Cuesta Angel, M. et al. “Multivalent antibodies: when design surpasses evolution.” Trends Biotechnol, 2010, vol. 28, pp. 355-362. [cited by applicant]
Dassa, B. et al. “Trans Protein Splicing of Cyanobacterial Split Inteins in Endogenous and Exogenous Combinations. Biochemistry,” 2007, vol. 46, pp. 322-330. [cited by applicant]
Datsenko, K.A. et al. “One-step inactivation of chromosomal genes in [cited by applicant]
Dictionary “Unique” accessed from dictionary.com on Mar. 20, 2023 (Year: 2023), p. 1. [cited by applicant]
Ducancel, F. et al. “Recombinant Colorimetric Antibodies: Construction and characterization of a Bifunctional F(ab)2/Alkaline Phosphatase Conjugate Produced in [cited by applicant]
Ezkurdia, I. et al. “Protein Structural Domains: Definition and Prediction,” Curr Protoc Protein Sci., Supplement 66, Nov. 2011, Chapter 2, doi: 10.1002/0471140864.ps0214s66, pp. 2.14.1-2.14.16. [cited by applicant]
Geller, B. L. “Antibacterial antisense,” Curr. Opin. Mol. Ther., 2005, vol. 7, pp. 109-113. [cited by applicant]
Gingrich, J.C. et al. “Multiplex Detection and Quantitation of Proteins on Western Blots Using Fluorescent Probes,” Biotechniques, Sep. 2000, vol. 29, No. 3, pp. 636-642. [cited by applicant]
Hentrich, C. et al. “Periplasmic expression of SpyTagged antibody fragments enables rapid modular antibody assembly” [cited by applicant]
IMGT definitions according to Lefranc M.-P., De R.K., Tomar N. Immunoinformatics of the V, C and G domains: IMGT® definitive system for IG, TR and IgSF, MH and MhSF, Immunoinformatics: From Biology to Informatics, 2014,… [cited by applicant]
Jia, L. et al. “Polymeric SpyCatcher scaffold enables bioconjugation in a ratio-controllable manner,” Biotechnology Journal, Mar. 16, 2017, vol. 12, No. 12, oi:[10.1002/biot.201700195]. [cited by applicant]
Keeble, A. H., Howarth, M., 2019, Insider information on successful covalent protein coupling with help from SpyBank. Methods in Enzymology. 617: 443-461, doi.org/10.1016/bs.mie.2018.12.010. [cited by applicant]
Keeble, A.H. et al. “Approaching infinite affinity through engineering of peptide-protein interaction,” Proc. Natl. Acad. Sci., 2019, vol. 116, pp. 26526-26533. [cited by applicant]
Keiler, K. et al. “Identification of Active Site Residues of the Tsp Protease,” J. Biol. Chem., 1995, vol. 270, No. 48, pp. 28864-28868. [cited by applicant]
Knappik, A. et al. “Recombinant antibody Expression and Purification,” In: Walker, J.M. editor. The Protein Protocols Handbook. 3rd edition. New York: Humana Press Inc., 2009, pp. 1929-1943. [cited by applicant]
Knappik, A. et al. “Development of Recombinant Human IgA for Anticardiolipin Antibodies Assay Standardization,” Annals of the New York Academy of Sciences, 2009, vol. 1173, pp. 190-198. [cited by applicant]
Ko, S. et al. “Engineering antibodies for dual specificity and enhanced potency” [cited by applicant]
Li et al. “Structural Analysis and Optimization of the Covalent Association between SpyCatcher and a Peptide Tag,” J. Mol. Biol., 2014, vol. 426, No. 2, pp. 309-317. [cited by applicant]
Liu, X.-Q. et al. “Split dnaE Genes Encoding Multiple Novel Inteins in Trichodesmium erythraeum,” J. Biol. Chem., 2003, vol. 278, pp. 26315-26318. [cited by applicant]
Mauro, V.P. “Codon Optimization in the Production of Recombinant Biotherapeutics: Potential Risks and Considerations.” BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy, Feb. 1, 2018, vol. 32, N… [cited by applicant]
Nguyen et al. “Butelase-mediated cyclization and ligation of peptides and proteins,” Nature protocols, 2016, vol. 11, No. 10, pp. 1977-1988. [cited by applicant]
Pack, P. et al. “Miniantibodies: use of Amphipathic Helices to Produce Functional, Flexibly Linked Dimeric Fv Fragments with High Avidity in [cited by applicant]
Pack, P. et al. “Tetravalent Miniantibodies with High Avidity Assembling in [cited by applicant]
Pallen, M. et al. “The HtrA family of serine proteases” Mol Microbiol, 1997, 26:209-21. [cited by applicant]
Pluckthun, A. “Antibodies from [cited by applicant]
Prassler, J. et al. “HuCAL Platinum, a synthetic Fab Library Optimized for Sequence Diversity and Superior Performance in Mammalian Expression Systems,” J. Mol. Biol., 2011, vol. 413, No. 1, pp. 261-278. [cited by applicant]
Prouty, W.F. et al. “Effects of Protease Inhibitors on Protein Breakdown in [cited by applicant]
Qi, F. et al. “Evolutionary analysis of polyproline motifs in [cited by applicant]
Rheinnecker, M. et al. “Multivalent Antibody Fragments with High Functional Affinity for a Tumor-Associated Carbohydrate Antigen.” J Immunol, 1996, vol. 157, pp. 2989-2997. [cited by applicant]
Shah, N. et al. “Split Inteins: Nature's Protein Ligases,” Israel Journal of Chemistry, 2011, vol. 5, (8-9), pp. 854-861. [cited by applicant]
Silber, K. et al. “Tsp: a tail-specific protease that selectively degrades proteins with nonpolar C termini,” PNAS, 1991, vol. 89, pp. 295-299. [cited by applicant]
Skerra and Pluckthun, “Assembly of a Functional Immunoglobulin Fv Fragment in [cited by applicant]
Sutherland, A. R. et al. “Post-translational Assembly of Protein Parts into Complex Devices by Using SpyTag/SpyCatcher Protein Ligase” Chem BioChem, 2019, pp. 319-328, vol. 20. [cited by applicant]
Tan et al. “Kinetic Controlled Tag-Catcher Interactions for Directed Covalent Protein Assembly,” PLOS ONE, 2016, vol. 11, No. 10, e0165074. [cited by applicant]
Waugh, D.S. “Crystal structures of MBP fusion proteins,” Protein Sci., Dec. 19, 2015, vol. 25, pp. 559-571. [cited by applicant]
Wu, C. et al. “Twin disulfides for orthogonal disulfide pairing and the directed folding of multicyclic peptides,” Nat Chem., 2012, vol. 4, pp. 1044-1049. [cited by applicant]
Wu, H. et al. “Protein trans-splicing by a split intein encoded in a split DnaE gene of [cited by applicant]
Zettler, J. et al. “The Naturally Split Npu DnaE intein exhibits an extraordinarily high rate in the protein trans-splicing reaction,” FEBS Letters, 2009, 553:909-914. [cited by applicant]
Bhatta, P. et al. “Bispecific antibody target pair discovery by high-throughputphenotypic screening using in vitro combinatorial Fab libraries” [cited by applicant]
Deng, J.-R. et al.“Chemoselective and photocleavable cysteinemodification of peptides and proteins using isoxazoliniums” [cited by applicant]
Dovala, D. et al. “Rapid analysis of protein expression and solubility with the SpyTag-SpyCatcher system” [cited by applicant]
Hartzell, E.J. et al. “Engineering a Blue Light Inducible SpyTag System (BLISS)” [cited by applicant]
Hentrich, C., et al. “Engineered Reversible Inhibition of SpyCatcher Reactivity Enables Rapid Generation of Bispecific Antibodies” [cited by applicant]
Hofmann, T. et al. “Intein mediated high throughput screening for bispecific antibodies” [cited by applicant]
Kantner, T. et al. “In Situ Quenching of Trialkylphosphine Reducing Agents Using Water-Soluble PEG-Azides Improves Maleimide Conjugation to Proteins” [cited by applicant]
Ma, J. et al. “Bispecific Antibodies: From Research to Clinical Application” [cited by applicant]
Mahmoodi, M. M. et al. “6-Bromo-7-hydroxy-3-methylcoumarin (mBhc) is an efficient multi-photon labile protecting group for thiol caging and three dimensional chemical patterning” [cited by applicant]
Mei, L. et al. “Rapid Production of Bispecific Antibodies from Off-the-Shelf IgGs with High Yield and Purity” [cited by applicant]
Min, D. et al. “A simple DNA handle attachment method for single molecule mechanical manipulation experiments” [cited by applicant]
Pessino, V. et al. “Covalent Protein Labeling by SpyTag-SpyCatcher in Fixed Cells for Super-Resolution Microscopy” [cited by applicant]